The stem cell company NextCell Pharma is preparing for a pivotal phase III trial

Report this content

NextCell Pharma AB ("NextCell") announces that CEO Mathias Svahn will present a status update of the ongoing clinical trials at the Stockholm Corporate Finance Life Science Seminar held at Berns in Stockholm today, March 11.

NextCell Pharma is currently running two parallel trials with ProTrans (Protrans-1 Phase I/II and ProTrans-Repeat) for the treatment of patients with type 1-diabetes. Ten out of a total of 15 patients in the phase II part of ProTrans-1 (ProTrans 2) have now left the trial and the last patient's last visit is scheduled for the end of June/July 2020. Thereafter, data will be analyzed and results are expected to be presented in September.

NextCell is now preparing for the next step in the clinical trial program. In case of positive data from the phase II part, an application for a pivotal phase III study will be submitted.

In December 2019, NextCell presented positive efficacy data from the phase I part of the study. Although designed solely for safety analysis, a dose-dependent effect of treatment could be shown.

Stockholm Corporate Finance, in collaboration with Financial Hearings, arranges the Capital Market Day for the twelfth year in a row and offers investors, analysts and the media to meet companies in Life Science and Health Care. The seminar will take place at Berns in Stockholm 11-12 March and NextCell's presentation will be held on 11 March at 11.15 AM.

The presentation can be followed via a webcast, see link below:

Stay up to date with the latest development in NextCell Pharma




For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Sofia Fredrikson, CFO

Phone: 08-735 5595




About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell

Pharma AB develops ProTrans, a drug candidate consisting of stem cells for the primary treatment of autoimmune and inflammatory diseases as well as for use in kidney transplants. ProTrans consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Scandinavia´s largest stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.


Documents & Links